CLEVELAND, Oct. 16, 2018 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian® and MRIdian Linac – the world’s only FDA-cleared MRI-guided radiation therapy systems – will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO). ASTRO 2018 will be held October 21-24, 2018 in San Antonio, TX and will include a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes of ViewRay’s MRIdian and MRIdian Linac.
At ASTRO, ViewRay will highlight the four key elements that differentiate MRIdian Linac from any other radiotherapy system on the market today. These unique capabilities include:
- Visualization of the tumor and surrounding organs with high-definition, high-contrast MR imaging (SEE)
- Daily on-table treatment adaptation to accommodate anatomical positioning changes that regularly occur from one day of treatment to the next (SHAPE)
- Real-time soft tissue image guidance and beam control during radiation delivery (STRIKE)
- Ability to fit into existing standard linear accelerator vaults (SIZE)
Visitors to the company’s booth # 1121 can see these one-of-a-kind features first-hand in an up-close simulated MRI-guided ROAR™ (Real-time On-table Adaptive Radiotherapy) patient treatment. ViewRay’s booth will also feature presentations from seven MRIdian users covering a spectrum of topics from commissioning and re-contouring to novel applications and real-time on-table adaptive therapy.
Two Industry Expert Theater sessions at ASTRO will highlight imaging of tumor response and clinical outcomes using MRIdian MRI-guided Radiotherapy. Related sessions include:
- “MRI-Guided Radiotherapy: Imaging of Tumor Response to Therapy”, to be held Sunday, October 21 from 2:45–3:45 p.m. with presentations by Carri Glide-Hurst, Ph.D. (Henry Ford), Nicola Dinapoli, M.D., Ph.D. (Gemelli), and John Chetley Ford, Ph.D. (University of Miami)
- “MRI-Guided Radiotherapy Clinical Outcomes: A Summary of Prospective Trials” to be held Tuesday, October 23from 12:30–1:30 p.m. with presentations by Michael Bassetti, M.D., Ph.D. (University of Wisconsin), Imran Zoberi, M.D. (Washington University), and Amar Kishan, M.D. (UCLA)
As part of the ASTRO scientific sessions, an interactive panel entitled “Current and Future Applications for MR-guided Radiotherapy with Real-time Adaptive Radiotherapy” will be held on Tuesday, October 23 from 1:00 p.m. – 2:30 p.m. to further explore MR-guided radiotherapy implementation, early clinical outcomes, and areas of future research. Early clinical experience suggests that use of MRI-guided radiotherapy, particularly utilizing on-table adaptive radiotherapy with daily assessment of plan quality and optimization, may translate to a clinical benefit in locally advanced pancreatic cancer, liver tumors and oligometastatic disease. The panel will feature presentations from Percy Lee, M.D. and Michael Steinberg, M.D. from UCLA, Olga Green, Ph.D. from Washington University School of Medicine in St. Louis, and Benjamin Movsas, M.D. from Henry Ford Health System.
For a full schedule of MRIdian-focused presentations and events at ASTRO or to book a product demonstration, please visit https://go.viewray.com/ASTRO_2018.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to the presentations to be featured at ASTRO and related clinical experience and patient outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.